Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2010
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. Advances in the understanding of the molecular mechanisms of GIST pathogenesis have resulted for last years in the emerging of GIST as a distinct sarcoma entity. The paper describes guidelines for diagnostics and therapy of these tumors based on scientific basis and experts’ experience, which are commonly accepted and worth to recommend. Overexpression of KIT receptor, as a consequence of mutation of protooncogene KIT, is highly specific for GIST and enable for detection by immunohistochemistry staining (CD117) in tumor specimens. It is the most important criterion in microscopic diagnostics and indications for treatment with small-molecule tyrosine kinas inhibitors. Sending material for molecular analysis is strongly recommended (for KIT and PDGFRA genotyping). Radical surgery is still the mainstay treatment for primary, localized, resectable GISTs, although high percentages of the patients after potentially curative operations develop recurrent or metastatic disease. In inoperable/metastatic lesions the treatment of choice is tyrosine kinase inhibitor – imatynib mesylate – the first effective systemic therapy in advanced CD117(+) GIST. Recommended initial dose should be 400 mg daily (800 mg for exon 9 KIT mutants). Monitoring of the therapy should be based on serial computed tomography imaging of abdominal cavity with the assessment of changes of tumor size and density. In case of disease progression the increase of imatynib dose to 800 mg daily is recommended and if further progression exists – sunitinib in the initial dose 50 mg daily should be introduced. Clinical trials evaluating the role of surgery in combination of imatynib and the efficacy of other molecular targeted drugs in resistant cases are ongoing. Existing data indicate beneficial role of adjuvant imatynib therapy in terms of relapse-free survival, especially in group of patients with significant risk of relapse.. Presented recommendations for diagnostics and therapy of GIST should be practically implemented by physicians involved in management of GIST patients in Poland. The including GIST cases in national Clinical Registry (http://gist.coi.waw.pl) and standard treatment of patients in multidisciplinary team with expertise in GIST therapy, as well as enrollment of new cases to prospective clinical trials, are recommended.
Authors and Affiliations
Piotr Rutkowski
Keywords
Related Articles
- EP ID EP53084
- DOI -
- Views 231
- Downloads 0
Rola i miejsce jakości życia w nowoczesnym leczeniu chorych na raka płuca
Jakość życia to osobisty sposób postrzegania przez jednostkę pozycji zajmowanej w życiu w kontekście kultury i systemu wartości oraz w odniesieniu do stawianych sobie celów, oczekiwań i obaw. Chorzy zmieniają postrzegani...
Aktywność fizyczna a nowotwory
Dane epidemiologiczne wskazują, że aktywność fizyczna zmniejsza ryzyko wystąpienia raka piersi i raka jelita grubego. Najprawdopodobniej przyczynia się również do obniżenia ryzyka zachorowania na raka prostaty, trzonu ma...
Late relapse of chronic myeloid leukemia after allogeneic stem cell tranplan
Chronic myeloid leukemia now is a disease which in the most cases is well manageable with tyrosine kinase inhibitors treatment. Still however the only potentially curable therapeutic approach is for chronic myeloid leuke...
Novel oral anticoagulants in the treatment of cancer patients
Cancer and its treatment are well-recognized risk factors for venous thromboembolism. The risk of thrombotic complications increases 4–7-fold in cancer patients and coexistence of both pathologies is associated with shor...
Breast cancer heterogeneity - report from IMPAKT Breast Cancer Conference
On 2–4 May 2013, in Brussels took place the 5th IMPAKT conference on translational research in breast cancer. The most important issue raised during the conference was the phenomenon of breast cancer heterogeneity, both...